Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
James F. Donohue, Eric D. Bateman, Anthony D'Urzo, Pomy Shrestha, Anne Leselbaum, Alejhandra Lei
European Respiratory Journal 2014 44: P287; DOI:
James F. Donohue
1Department of Internal Medicine, University of North Carolina, Chapel Hill, NC,
Eric D. Bateman
2Division of Pulmonology, University of Cape Town Lung Institute, Cape Town, South Africa
Anthony D'Urzo
3Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, Canada
Pomy Shrestha
4Forest Research Institute, Forest Laboratories Inc, NJ,
Anne Leselbaum
5Almirall R&D Centre, Almirall S.A., Barcelona, Spain
Alejhandra Lei
5Almirall R&D Centre, Almirall S.A., Barcelona, Spain
Vol 44 Issue Suppl 58
Table of Contents
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
James F. Donohue, Eric D. Bateman, Anthony D'Urzo, Pomy Shrestha, Anne Leselbaum, Alejhandra Lei
European Respiratory Journal Sep 2014, 44 (Suppl 58) P287;
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies
James F. Donohue, Eric D. Bateman, Anthony D'Urzo, Pomy Shrestha, Anne Leselbaum, Alejhandra Lei
European Respiratory Journal Sep 2014, 44 (Suppl 58) P287;